For this purpose, predictivity of BiotHER results with respect to RR, TTP and OS was retrospectively studied in a series of 54 patients with HER-2 amplified advanced breast cancer who had received Trastuzumab plus chemotherapy. The gene discussed is ERBB2; the disease is breast carcinoma.